Review top news and interview highlights from the week ending August 5, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
Avenge Bio previously presented positive preclinical data at the ASGCT 2022 meeting.
The principal investigator of the HOPE-2 trial discussed safety and efficacy of Capricor’s CAP-1002.
The FDA will consider RGX-121's BLA in an accelerated approval pathway.
UCART2022 is an allogeneic therapy that targets both CD20 and CD22.
Beam Therapeutics submitted an IND for BEAM-201 in June 2022.